A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease-Reference-Cited by-同舟云学术

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Published:2021-07-01 Issue:1 Volume:385 Page:35-45
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Schuppan Detlef¹,Mäki Markku¹,Lundin Knut E.A.¹,Isola Jorma¹,Friesing-Sosnik Tina¹,Taavela Juha¹,Popp Alina¹,Koskenpato Jari¹,Langhorst Jost¹,Hovde Øistein¹,Lähdeaho Marja-Leena¹,Fusco Stefano¹^ORCID,Schumann Michael¹,Török Helga P.¹,Kupcinskas Juozas¹,Zopf Yurdagül¹,Lohse Ansgar W.¹,Scheinin Mika¹,Kull Karin¹,Biedermann Luc¹,Byrnes Valerie¹,Stallmach Andreas¹,Jahnsen Jørgen¹,Zeitz Jonas¹,Mohrbacher Ralf¹,Greinwald Roland¹

Affiliation:

1. From the Institute of Translational Immunology and Celiac Center, Research Center for Immune Therapy, University Medical Center, Johannes Gutenberg University, Mainz (D.S., T.F.-S.), the Department of Internal and Integrative Medicine, Sozialstiftung Bamberg, Bamberg (J.L.), the Department of Integrative Medicine, University of Duisburg-Essen, Duisburg-Essen (J.L.), the Division of Gastroenterology, Hepatology, and Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen,...

Funder

Dr. Falk Pharma, Freiburg, Germany

German Ministry for Education and Research (BMBF), Ci3 Cluster for Immune Intervention, Clinical Development of Transglutaminase Inhibitors for the treatment of celiac disease

Research Center for Immune Therapy, Mainz University Medical Center

State Research Financing of the Expert Responsibility area of Tampere

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2032441

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of an 18F-labeled Nε-acryloyllysine piperazide for covalent targeting of transglutaminase 2;EJNMMI Radiopharmacy and Chemistry;2024-01-02

2. Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study;Gastroenterology;2024-01

3. Tissue transglutaminase: a multifunctional and multisite regulator in health and disease;Physiological Reviews;2024-01-01

4. Beta cell stress and type 1 diabetes;Stress: Immunology and Inflammation;2024

5. Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease;Pharmaceuticals;2023-12-20